What happens when the FDA lays off thousands, replaces leadership, and still decides which drugs Americans get?
This episode analyzes the FDA's drug approval trends in 2025, highlighting how agency layoffs and leadership changes initially slowed approvals before a recovery in the second half. It compares US and European company performance, examines key therapeutic areas like oncology and rare diseases, and discusses shifts in blockbuster drug projections and regulatory transparency.
